|Dr. Mark R. Dybul M.D.||Chief Exec. Officer & Director||430k||N/A||1963|
|Ms. Luisa Puche||Chief Financial Officer||280k||N/A||1964|
|Ms. Evelyn D'An||Consultant||83k||N/A||1963|
|Dr. Serhat GÃ¼mrÃ¼kcÃ¼||Co-Founder & Inventor||N/A||N/A||N/A|
|Dr. Wenshi Wang||Sr. VP of Operations||N/A||N/A||N/A|
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.
Enochian Biosciences, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 9. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 2; Compensation: 8.